Awakn Life Sciences Advances Treatment for Alcohol Use Disorder

LOS ANGELES- Awakn Life Sciences Corp. a biotechnology company, has made significant strides in the treatment of addiction, particularly Alcohol Use Disorder (AUD), with its recent investigative study on a proprietary S-ketamine oral thin film (OTF) formulation. The study highlighted the formulation’s potential, demonstrating significant dissociative effects and effectively reducing alcohol cravings in harmful drinkers.

This breakthrough follows on the heels of Awakn’s global licensing agreement with LTS Lohmann Therapie-Systeme AG, which granted the company access to critical Phase 1 clinical trial data and patents for the S-ketamine OTF. Capitalizing on this agreement, Awakn has earmarked its AWKN-002 program specifically for AUD treatment within the US market, with plans to progress to late-stage clinical trials after a forthcoming pre-IND meeting with the FDA scheduled for the first half of 2024.

The AWKN-002 program, when combined with manualized relapse prevention cognitive-behavioral therapy (CBT), promises to expand the availability of ketamine treatment. This is largely due to its rapid onset and offset of action, which presents a significant advantage over traditional intravenous ketamine treatments. Such innovations are in line with Awakn’s mission to extend life-saving addiction treatments to a broader segment of patients in need.

Awakn Life Sciences’ commitment to pioneering advancements in the field of addiction treatment underscores the company’s role as a leader in developing effective, patient-centered solutions. As the company moves forward with its clinical trials, its efforts could mark a significant turning point in the treatment of AUD, potentially offering new hope to thousands of individuals struggling with addiction.